<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Chemother. Pharmacol</journal-id><journal-title-group><journal-title>Cancer Chemotherapy and Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0344-5704</issn><issn pub-type="epub">1432-0843</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27113368</article-id><article-id pub-id-type="pmc">4969877</article-id><article-id pub-id-type="publisher-id">3016</article-id><article-id pub-id-type="doi">10.1007/s00280-016-3016-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tanaka</surname><given-names>Yoshihiro</given-names></name><address><email>yoshihirotana11@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoshida</surname><given-names>Kazuhiro</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Atsuko</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tanahashi</surname><given-names>Toshiyuki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Okumura</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuhashi</surname><given-names>Nobuhisa</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamaguchi</surname><given-names>Kazuya</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Miyazaki</surname><given-names>Tatsuhiko</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194 Japan </aff><aff id="Aff2"><label>2</label>Department of Pathology, Gifu University Hospital, Gifu, Japan </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>4</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>77</volume><fpage>1153</fpage><lpage>1155</lpage><permissions><copyright-statement>&#x000a9; Springer-Verlag Berlin Heidelberg 2016</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e85" ext-link-type="doi" xlink:href="10.1007/s00280-016-2985-y"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Cancer Chemother Pharmacol DOI 10.1007/s00280-016-2985-y</title><p>Unfortunately, the online published article has error in Table&#x000a0;5. The correct Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> is given here. The original article has been corrected.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Docetaxel, CDDP, and 5-Fu for advanced esophageal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">References (first author)</th><th align="left">Target</th><th align="left">Regimen (/m<sup>2</sup>)</th><th align="left">Phase</th><th align="left">Cases, <italic>n</italic>
</th><th align="left">Grade 3/4 leukopenia (%)</th><th align="left">Grade 3/4 neutropenia (%)</th><th align="left">Febrile neutropenia (%)</th><th align="left">Response rate (%)</th><th align="left">Histopathological response rate (&#x0003e;grade 2) (%)</th><th align="left">Histopathological complete response rate (grade 3) (%)</th><th align="left">Dose reduction rate in the second cycle (%)</th><th align="left">Protocol completion rate (%)</th></tr></thead><tbody><tr><td align="left">Takahashi [32]</td><td align="left">Esophageal cancer (SCC)<break/>Stages III, IV</td><td align="left">D: 50 (day 1)<break/>C: 70 (day 1)<break/>F: 700 (days 1&#x02013;5)/3 wks</td><td align="left">I/II</td><td align="left">39</td><td align="left">53.8</td><td align="left">43.6</td><td align="left">12.8</td><td align="left">66.6</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Osaka [33]</td><td align="left">Esophageal cancer (SCC)<break/>Stages III, IV</td><td align="left">D: 60 (day 1)<break/>C: 60 (day 1)<break/>F: 800 (days 1&#x02013;5)/3&#x02013;4 wks&#x000a0;&#x000d7;&#x000a0;2 courses</td><td align="left">II</td><td align="left">30</td><td align="left">33.3</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">83.3 (primary lesion)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">96.7</td></tr><tr><td align="left">Yamasaki [23]</td><td align="left">Esophageal cancer (SCC)<break/>Stages III, IV</td><td align="left">D: 70 (day 1)<break/>C: 70 (day 1)<break/>F: 700 (days 1&#x02013;5)/3 wks&#x000a0;&#x000d7;&#x000a0;2 courses</td><td align="left">I/II</td><td align="left">9/40</td><td align="left">72.5</td><td align="left">90</td><td align="left">10</td><td align="left">72.5</td><td align="left">40</td><td align="left">25</td><td align="left">&#x02013;</td><td align="left">82.5</td></tr><tr><td align="left">Tamura [34]</td><td align="left">Esophageal cancer (SCC)<break/>Stage IV</td><td align="left">D: 60 (day 1)<break/>C: 70 (day 1)<break/>F: 600 (days 1&#x02013;5)/4 wks&#x000a0;&#x000d7;&#x000a0;2 courses</td><td align="left">II</td><td align="left">29</td><td align="left">52</td><td align="left">76</td><td align="left">21</td><td align="left">34.5 (confirmed cases)</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">13.8</td><td align="left">&#x02013;</td></tr><tr><td align="left">Ferri [35]</td><td align="left">Esophageal cancer and gastric cancer (AD)<break/>Stages II, III, IV</td><td align="left">D: 75 (day 1)<break/>C: 75 (day 1)<break/>F: 750 (days 1&#x02013;5)/3 wks&#x000a0;&#x000d7;&#x000a0;3 courses</td><td align="left">II</td><td align="left">43</td><td align="left">&#x02013;</td><td align="left">20</td><td align="left">2.3</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">9.8</td><td align="left">&#x02013;</td><td align="left">95</td></tr><tr><td align="left">Hara [36]</td><td align="left">Esophageal cancer (SCC)<break/>Stages IIA, IIB, III</td><td align="left">D: 70 (day 1)<break/>C: 70 (day 1)<break/>F: 750 (days 1&#x02013;5)<break/>D: 75 (day 1)<break/>C: 75 (day 1)<break/>F: 750 (days 1&#x02013;5)/3 wks&#x000a0;&#x000d7;&#x000a0;3 courses</td><td align="left">II</td><td align="left">42</td><td align="left">45.2</td><td align="left">83.3</td><td align="left">2.4</td><td align="left">64.3</td><td align="left">51</td><td align="left">17</td><td align="left">64.3</td><td align="left">95.2</td></tr><tr><td align="left">Watanabe [37]</td><td align="left">Esophageal cancer (SCC, AD)<break/>Stages IIB, III, IVA, IVB (TNM6)</td><td align="left">D: 60 (day 1)<break/>C:6 (days 1&#x02013;5)<break/>F: 350 (days 1&#x02013;5)/3 wks&#x000a0;&#x000d7;&#x000a0;2 courses</td><td align="left">Prospective intension-to-treat</td><td align="left">50</td><td align="left">&#x02013;</td><td align="left">78.2</td><td align="left">14.5</td><td align="left">53.7</td><td align="left">26</td><td align="left">12</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Hironaka [38]</td><td align="left">Esophageal cancer (SCC, AS, B)<break/>Stage IV</td><td align="left">D: 30 (days 1, 15)<break/>C: 80 (day 1)<break/>F: 800 (days 1&#x02013;5)/4 wks</td><td align="left">I/II</td><td align="left">10/52</td><td align="left">9.1</td><td align="left">25.5</td><td align="left">0</td><td align="left">62</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Current study</td><td align="left">Esophageal cancer (SCC)<break/>Stages II, III</td><td align="left">D: 35 (days 1, 15)<break/>C:40 (days 1, 15)<break/>F: 400 (days 1&#x02013;5, 15&#x02013;19)</td><td align="left">II</td><td align="left">32</td><td align="left">12.5</td><td align="left">31.3</td><td align="left">0</td><td align="left">90.3</td><td align="left">53.2</td><td align="left">21.9</td><td align="left">0</td><td align="left">100</td></tr></tbody></table><table-wrap-foot><p>
<italic>SCC</italic> squamous cell carcinoma, <italic>AD</italic> adenocarcinoma, <italic>AS</italic> adenosquamous carcinoma, <italic>B</italic> basaloid carcinoma, <italic>D</italic> docetaxel, <italic>C</italic> cisplatin, <italic>F</italic> fluorouracil</p></table-wrap-foot></table-wrap></p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s00280-016-2985-y.</p></fn></fn-group></back></article>